Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on oncology that completed its business combination with LifeSci Acquisition Corp, a SPAC sponsored by LifeSci Capital LLC, in late 2020. The S-1 registration statement filed January 29, 2021 reflects the post-merger public entity, with the underlying blank-check vehicle having conducted its IPO in 2020. Vincerx is advancing a pipeline of novel therapeutics targeting hematologic malignancies, including its lead candidate VIP152, a selective CDK9 inhibitor. The combined company began trading on Nasdaq following the de-SPAC transaction. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on Vincerx and hundreds of other de-SPAC companies.